Innovation

Shining a light on the treatment of CNS disorders and cancer care.

SK Life Science is here listening to the needs of healthcare providers, patients, caregivers, advocates, and scientists. We are developing new molecules, enhancing advocacy efforts, and providing solutions that change what’s possible in the treatment of CNS disorders and cancer care.

Our Medicines

SK Life Science is committed to accelerating the development of next generation treatments for CNS disorders and cancer care. SK Biopharmaceuticals and SK Life Science independently developed XCOPRI® (cenobamate tablets) CV from inception through FDA approval.

For More Information

• XCOPRI Website
• XCOPRI Medication Guide
• XCOPRI Prescribing Information
• SK Life Science Navigator Program for Patient Access

The two companies also discovered and licensed-out the FDA and EMA-approved treatment for sleep disorders after completing phase 1 clinical trials.

U.S. Patent Rights For Products

This website is provided to satisfy the virtual patent marking provisions of the United States, including relevant provisions of the America Invents Act and 35 U.S. Code 287 (a).

The following products are protected by the associated U.S. patents set forth in the table below. The list is subject to change due to issuance of additional patents, product changes and other circumstances. The absence of a U.S. Patent number from the list does not constitute a waiver of the patent, trademark, or other intellectual property rights pertaining to the product.

• XCOPRI®
  (cenobamate tablets) CV
  U.S. Patent No. 7,598,279
  U.S. Patent No. 11,654,133

Our Clinical Trials

We are committed to conducting diverse, global clinical trials. With a commitment to safety, we place our patients at the center of everything we do.

To address the needs of people living with a central nervous system (CNS) disorder, we are conducting the following clinical trials:

• Global Primary Generalized Tonic-Clonic (PGTC) Seizures Clinical Trial
  Our global Phase 3 Open Label Safety Study for patients 12 years of age and older had sites in the U.S. as well as Bulgaria, Czechia, Georgia, Hungary, Poland, Slovakia, and Ukraine.
• Global Pediatric Clinical Trial
  We are currently enrolling in a Phase 3 Open Label Safety Study for patients between the ages of 2 and 3. The trial is currently recruiting in the U.S. as well as in Australia, Germany, Hungary, Poland, South Korea, and Spain.
• Global LGS DISCOVER Study
  The LGS DISCOVER study is evaluating whether an investigational drug can decrease the number of seizures in patients 4-55 years of age living with Lennox-Gastaut syndrome. The trial is currently recruiting in Australia, Colombia, Germany, Greece, Hungary, Italy, Korea, Mexico, Poland, Portugal, Serbia, Spain, Taiwan, and the U.S. For more information, please visit www.LGSDiscoverStudy.com.
• Monotherapy Study
  This is an open-label study to evaluate the effectiveness, safety and tolerability of an investigational drug used as a monotherapy in newly diagnosed or recurrent partial-onset seizures adult patients between the ages of 18 and 74.

Leveraging Technologies to Include:

• Target-based drug discovery techniques
• High throughput organic screening (HTOs)/high content screening (HCS)
• Computer-aided drug design (CADD)
• Combinatorial chemistry

Key R&D Sectors:

We deploy our technologies in the areas of biology/discovery, medicinal chemistry, and pharmacology. The goal of research in these areas is to bring meaningful products to market.